184 related articles for article (PubMed ID: 18686943)
1. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Kodimuthali A; Jabaris SS; Pal M
J Med Chem; 2008 Sep; 51(18):5471-89. PubMed ID: 18686943
[No Abstract] [Full Text] [Related]
2. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Xia XD; Dai YR; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829
[No Abstract] [Full Text] [Related]
3. Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
Tait A; Luppi A; Hatzelmann A; Fossa P; Mosti L
Bioorg Med Chem; 2005 Feb; 13(4):1393-402. PubMed ID: 15670947
[TBL] [Abstract][Full Text] [Related]
4. CC-10004 .
Khobzaoui M; Gutke HJ; Burnet M
Curr Opin Investig Drugs; 2005 May; 6(5):518-25. PubMed ID: 15912967
[TBL] [Abstract][Full Text] [Related]
5. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
6. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
7. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
Kreutzkamp B
Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460
[TBL] [Abstract][Full Text] [Related]
8. Are phosphodiesterase 4 inhibitors just more theophylline?
Boswell-Smith V; Cazzola M; Page CP
J Allergy Clin Immunol; 2006 Jun; 117(6):1237-43. PubMed ID: 16750981
[TBL] [Abstract][Full Text] [Related]
9. Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Grootendorst DC; Rabe KF
Curr Opin Allergy Clin Immunol; 2002 Feb; 2(1):61-7. PubMed ID: 11964752
[TBL] [Abstract][Full Text] [Related]
10. [Inflammatory lung and systemic disease].
Med Monatsschr Pharm; 2005 Jul; 28(7):254-5. PubMed ID: 16038131
[No Abstract] [Full Text] [Related]
11. Tetomilast.
O'Mahony S
IDrugs; 2005 Jun; 8(6):502-7. PubMed ID: 15906198
[TBL] [Abstract][Full Text] [Related]
12. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.
Giembycz MA
Curr Opin Pharmacol; 2005 Jun; 5(3):238-44. PubMed ID: 15907909
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar SG; Rajagopal D; Ray A
Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
[TBL] [Abstract][Full Text] [Related]
14. AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).
Gutke HJ; Guse JH; Khobzaoui M; Renukappa-Gutke T; Burnet M
Curr Opin Investig Drugs; 2005 Nov; 6(11):1149-58. PubMed ID: 16312137
[TBL] [Abstract][Full Text] [Related]
15. PDE4 inhibitors - a review of the current field.
Press NJ; Banner KH
Prog Med Chem; 2009; 47():37-74. PubMed ID: 19328289
[No Abstract] [Full Text] [Related]
16. [Modern therapy of COPD].
Pariente R; Aubier M
Bull Acad Natl Med; 2004; 188(1):67-74; discussion 74-5. PubMed ID: 15368926
[TBL] [Abstract][Full Text] [Related]
17. Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.
Donnell AF; Dollings PJ; Butera JA; Dietrich AJ; Lipinski KK; Ghavami A; Hirst WD
Bioorg Med Chem Lett; 2010 Apr; 20(7):2163-7. PubMed ID: 20202838
[TBL] [Abstract][Full Text] [Related]
18. Effects of KF19514, a phosphodiesterase 4 and 1 Inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma.
Kita T; Fujimura M; Myou S; Watanabe K; Waseda Y; Nakao S
Allergol Int; 2009 Jun; 58(2):267-75. PubMed ID: 19390238
[TBL] [Abstract][Full Text] [Related]
19. American Chemical Society - 229th National Meeting: bench to pilot plant.
Rotella DP
IDrugs; 2005 May; 8(5):390-1. PubMed ID: 15883918
[No Abstract] [Full Text] [Related]
20. Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
Taltavull J; Serrat J; Gràcia J; Gavaldà A; Córdoba M; Calama E; Montero JL; Andrés M; Miralpeix M; Vilella D; Hernández B; Beleta J; Ryder H; Pagès L
Eur J Med Chem; 2011 Oct; 46(10):4946-56. PubMed ID: 21871695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
